Roche Stock: Pharma Giant Keeps Guidance Despite Third-Quarter Sales Miss

2026-09-05

Roche (RHHBY) stock jumped Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook. The Swiss drugmaker pointed to newer medicines Vabysmo, Phesgo and Ocrevus for helping drive demand in the September quarter. Vabysmo is an eye disease treatment, Phesgo treats breast cancer and Ocrevus is a multiple sclerosis drug. Sales of Vabysmo and Phesgo topped…

Tags:
All News And Stock Ideas
Biotech And Pharma Stock News
Earnings
Roche
Tech Earnings

Roche Stock: Pharma Giant Keeps Guidance Despite Third-Quarter Sales Miss

Tags: